RESUMO
Peroxynitrite (ONOO(-)), the product of nitric oxide (NO(radical)) and superoxide (O(2)(-radical)), is believed to be a major contributor to immunotoxicity when produced by activated cells expressing inducible nitric oxide synthase (iNOS). Uric acid (UA) is a natural scavenger of ONOO(-) that is present at high levels in the sera of humans and other higher order primates relative to most lower mammals. We have previously shown that UA treatment is therapeutic in experimental allergic encephalomyelitis (EAE), a rodent model of multiple sclerosis (MS). In this study we have examined the effect of UA therapy on the dynamics of the appearance of iNOS-positive cells in central nervous system (CNS) tissue of mice subjected to the stimuli that cause EAE. The results indicate that UA prevents activated monocytes from entering CNS tissue where they may contribute to the pathogenesis of MS and other CNS diseases.
Assuntos
Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/metabolismo , Monócitos/imunologia , Proteína Básica da Mielina/imunologia , Proteína Básica da Mielina/metabolismo , Ácido Úrico/farmacocinética , Animais , Barreira Hematoencefálica/fisiologia , Modelos Animais de Doenças , Feminino , Radicais Livres/metabolismo , Regulação Enzimológica da Expressão Gênica/imunologia , Imunização , Peroxidação de Lipídeos/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos , Esclerose Múltipla/imunologia , Esclerose Múltipla/metabolismo , Nitratos/metabolismo , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/genética , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , RNA Mensageiro/análiseRESUMO
Following the immunization of BALB/c mice with B. pertussis toxin, monoclonal antibodies (McAb) to the antigens of human epithelium, both dermal (the basal, superbasal or all epidermis levels) and thymic (the epithelium of the medullary zone, the cortical and medullary epithelium around Hassall's corpuscles), have been obtained. McAb have been obtained as the result of the polyclonal activation of autoreactive B-cells with B. pertussis toxin. McAb thus obtained can be used for the determination of the corresponding antigens in the epithelial tissues of the thymus and other organs in man, as well as for the diagnosis of tumors, histogenetically related to integumentary tissues of the epidermal genesis.
Assuntos
Anticorpos Monoclonais/biossíntese , Epitopos/imunologia , Ativação Linfocitária/efeitos dos fármacos , Toxina Pertussis , Pele/imunologia , Timo/imunologia , Fatores de Virulência de Bordetella/farmacologia , Animais , Reações Antígeno-Anticorpo , Linfócitos B/efeitos dos fármacos , Linfócitos B/imunologia , Epitélio/imunologia , Imunofluorescência , Humanos , Hibridomas/imunologia , Imunização , Camundongos , Camundongos Endogâmicos BALB CRESUMO
Hybridomas synthetizing monoclonal antibodies (McAb) to B. pertussis toxin (BPT) and endotoxin, or lipopolysaccharide (LPS), were obtained. The specificity of McAb to BPT was confirmed in the leukocytosis-stimulating factor neutralization test. Two hybridomas synthetized McAb, seemingly active against the common determinant of BPT and LPS. The McAb of one hybridoma reacted with the crude extract of BPT.
Assuntos
Anticorpos Monoclonais/biossíntese , Hibridomas/imunologia , Toxina Pertussis , Fatores de Virulência de Bordetella/imunologia , Animais , Anticorpos Monoclonais/análise , Anticorpos Monoclonais/isolamento & purificação , Especificidade de Anticorpos , Antígenos de Bactérias/imunologia , Imunização , Técnicas Imunológicas , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos CBARESUMO
Immunomorphological studies by indirect immunofluorescent method using monoclonal antibodies to antigens of basal cells, suprabasal cells and basal membrane of the epidermis were carried out in 8 cases of squamous-cell skin cancer. Specific characteristics of localization of structure-specific antigens (as compared with normal human skin) in squamous-cell skin cancer are discussed.
Assuntos
Anticorpos Monoclonais , Antígenos de Neoplasias/análise , Carcinoma de Células Escamosas/imunologia , Epiderme/imunologia , Epitopos/análise , Neoplasias Cutâneas/imunologia , Idoso , Feminino , Fluoresceína-5-Isotiocianato , Fluoresceínas , Imunofluorescência , Corantes Fluorescentes , Humanos , Masculino , Pessoa de Meia-Idade , TiocianatosRESUMO
BACKGROUND: Nitric oxide has a wide variety of homeostatic and pathological effects. Control of the production of nitric oxide by the inducible form of the enzyme resides in the 5' promoter region of the gene. Although control of the murine isoform has been investigated, little is known about the functional aspects of the human analog. MATERIALS AND METHODS: A 3.9-kb 5' nontranslated region of the human gene was cloned, sequenced, and several reporter constructs prepared. The promoter-reporter constructs were transfected into human or murine monocytoid cells and reporter expression quantified following cytokine activation of the cells. The production of nitric oxide was also monitored. RESULTS: Although a murine promoter-reporter functioned efficiently in both human and mouse cells, the human constructs functioned only in human cells. The activity of the mouse construct increased progressively with the addition of activating cytokines, but the human promoter-reporter did not. Although interleukin 1 beta drove expression of the human inducible nitric oxide synthase reporter, actual expression of nitric oxide required both interleukin 1 beta and interferon-gamma. CONCLUSIONS: The data indicate that despite the significant homology between the human and mouse inducible nitric oxide synthase promoter sequence, control of the two genes is quite different. In addition to being more efficient in promoter activity, the murine promoter responds increasingly to cytokines that are not effective for the human analog. It is also apparent that human inducible nitric oxide synthase is controlled at both the level of transcription and post-translationally.
Assuntos
Óxido Nítrico Sintase/biossíntese , Óxido Nítrico Sintase/genética , Regiões Promotoras Genéticas , Transfecção , Animais , Sequência de Bases , Linhagem Celular , Sequência Consenso , Primers do DNA , Feminino , Genes Reporter , Biblioteca Genômica , Humanos , Luciferases/biossíntese , Macrófagos , Camundongos , Dados de Sequência Molecular , Placenta/enzimologia , Reação em Cadeia da Polimerase/métodos , Gravidez , Proteínas Recombinantes de Fusão/biossíntese , Homologia de Sequência do Ácido NucleicoRESUMO
Uric acid (UA), a product of purine metabolism, is a known scavenger of peroxynitrite (ONOO(-)), which has been implicated in the pathogenesis of multiple sclerosis and experimental allergic encephalomyelitis (EAE). To determine whether the known therapeutic action of UA in EAE is mediated through its capacity to inactivate ONOO(-) or some other immunoregulatory phenomenon, the effects of UA on Ag presentation, T cell reactivity, Ab production, and evidence of CNS inflammation were assessed. The inclusion of physiological levels of UA in culture effectively inhibited ONOO(-)-mediated oxidation as well as tyrosine nitration, which has been associated with damage in EAE and multiple sclerosis, but had no inhibitory effect on the T cell-proliferative response to myelin basic protein (MBP) or on APC function. In addition, UA treatment was found to have no notable effect on the development of the immune response to MBP in vivo, as measured by the production of MBP-specific Ab and the induction of MBP-specific T cells. The appearance of cells expressing mRNA for inducible NO synthase in the circulation of MBP-immunized mice was also unaffected by UA treatment. However, in UA-treated animals, the blood-CNS barrier breakdown normally associated with EAE did not occur, and inducible NO synthase-positive cells most often failed to reach CNS tissue. These findings are consistent with the notion that UA is therapeutic in EAE by inactivating ONOO(-), or a related molecule, which is produced by activated monocytes and contributes to both enhanced blood-CNS barrier permeability as well as CNS tissue pathology.
Assuntos
Barreira Hematoencefálica/imunologia , Movimento Celular/imunologia , Sistema Nervoso Central/imunologia , Sistema Nervoso Central/patologia , Encefalomielite Autoimune Experimental/metabolismo , Encefalomielite Autoimune Experimental/patologia , Sequestradores de Radicais Livres/farmacologia , Nitratos/metabolismo , Ácido Úrico/farmacologia , Animais , Barreira Hematoencefálica/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Permeabilidade Capilar/imunologia , Movimento Celular/efeitos dos fármacos , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/fisiopatologia , Feminino , Sequestradores de Radicais Livres/administração & dosagem , Sequestradores de Radicais Livres/metabolismo , Injeções Intraperitoneais , Injeções Subcutâneas , Macrófagos Peritoneais/efeitos dos fármacos , Macrófagos Peritoneais/imunologia , Macrófagos Peritoneais/metabolismo , Camundongos , Camundongos Endogâmicos , Proteína Básica da Mielina/administração & dosagem , Proteína Básica da Mielina/imunologia , Nitratos/antagonistas & inibidores , Oxirredução , Ácido Úrico/administração & dosagem , Ácido Úrico/metabolismoRESUMO
A number of hybridomas against different determinants of R. prowazekii were obtained by hybridization of splenocytes from BALB/c mice immunized with whole cells or soluble antigens of the organism. Some of the monoclonal antibodies bound to thermolabile species specific protein of R. prowazekii and did not react with R. mooseri antigens (monoclonal antibodies series B4/4 and A3). Monoclonal antibodies C5/2 and A3/2 reacted with group specific thermostabile antigen which is common for both R. prowazekii and R. mooseri. Monoclonal antibodies against species specific antigen were found to be of Ig G2a subclass. The monoclonal antibodies can be used to identify R. prowazekii and R. mooseri and solve the problem of differentiating Rickettsiae of typhus group.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos de Bactérias/imunologia , Rickettsia prowazekii/imunologia , Animais , Imunofluorescência , Camundongos , Camundongos Endogâmicos BALB C , Especificidade da EspécieRESUMO
A panel of mAb (IgG1, IgG3, IgM) against Legionella pneumophila cytolysin (CL)-protease of 37 kDa was obtained. Subtyping of L. pneumophila strains of serogroup 1 by using mAb against CL (mAb-CL) was carried out. The results of comparative analysis of the specificity of mAb-CL and the panel of mAb kindly provided by Dr. J. M. Barbaree (Centers for Disease Control, Atlanta, GA) allowed us to recommend mAb-CL to be used as a diagnostic tool to reveal the pathogenicity of L. pneumophila strains of serogroup 1. Hybridomas were also raised in a syngenic system which produced anti-idiotypic mAb (mAb2) against anti-CL mAb B6/1. The Ab2 belonged to Ab2 gamma type: 1) Ab2 reacted with B6/1 Id only, 2) Ab2 inhibited the interaction of B6/1 Ab1 with CL, and 3) CL inhibited the reaction of Ab2 with Ab1. The use of Ab2 allowed us to show that B6/1 Id is expressed in 4 to 32% of serum antibodies during the primary and secondary immune responses of BALB/c mice to CL. Ab2 induced the production of anti-anti-idiotypic antibodies (Ab3) in BALB/c mice, and some of them reacted with CL. Thus, we have demonstrated the possibility of inducing an antibody response to CL (one of the main L. pneumophila pathogenic factors) in intact syngenic mice with anti-idiotypic antibodies.
Assuntos
Anticorpos Anti-Idiotípicos/imunologia , Anticorpos Monoclonais/imunologia , Citotoxinas/imunologia , Legionella/imunologia , Animais , Anticorpos Antibacterianos/imunologia , Antígenos de Bactérias/imunologia , Proteínas de Bactérias/imunologia , Legionella/enzimologia , Camundongos , Camundongos Endogâmicos BALB CRESUMO
BACKGROUND: The production of nitric oxide by type II inducible nitric oxide synthase (type II NOS) gene is controlled at least in part by transcriptional activation. Although the murine and human type II NOS genes share significant sequence homology, they differ in the induction stimuli required for activation. MATERIALS AND METHODS: The A549 human and murine RAW 264.7 cell lines were cultured in the presence of inducers of the type II NOS gene and exposed to specific inhibitors of phosphatidyl choline-specific phospholipase C, NF-kappa B, and endocytosis, as well as to reagents that deplete stores of ATP or prevent the acidification of endosomes. The effect of these reagents on the induction of the type II NOS gene transcription, translation, and NO expression was studied using electromobility shift assays, Western blotting, and the detection of NO as nitrates, as appropriate. Additionally, the ability of the native human type II NOS NF-kappa B recognition sequence to bind NF-kappa B was compared with a concensus sequence and with a mutated oligomer. RESULTS: Type II NOS production by both human and mouse cells could be prevented by the addition of the specific inhibitor of phosphatidylcholine-specific phospholipase C, D609, and of agents that interfere with the activation of NF-kappa B. Both mouse and human cells also required acidic endosome formation and the production of 1,2-diacylglycerol for type II NOS expression. Additionally, the native human type II NOS NF-kappa B recognition sequence bound NF-kappa B with significantly less affinity than did the recognition sequence derived from the human immunoglobulin light-chain gene promoter. CONCLUSIONS: These experiments show that whereas mouse cells can be activated by lipopolysaccharide to produce nitric oxide, and human cells require activation by a mixture of cytokines to produce nitric oxide, the intracellular activation pathway following receptor binding of these heterologous stimuli is shared. Additionally, NF-kappa B activation is necessary but not sufficient for inducible nitric oxide synthase production in human cells, in contrast to murine cells in which it serves as a complete inducer.
Assuntos
NF-kappa B/metabolismo , Óxido Nítrico Sintase/genética , Ativação Transcricional , Fosfolipases Tipo C/metabolismo , Animais , Antioxidantes/farmacologia , Western Blotting , Hidrocarbonetos Aromáticos com Pontes/farmacologia , Linhagem Celular , Citocinas/metabolismo , Epitélio , Expressão Gênica , Humanos , Metabolismo dos Lipídeos , Pulmão/citologia , Pulmão/metabolismo , Macrófagos/citologia , Macrófagos/metabolismo , Camundongos , NF-kappa B/antagonistas & inibidores , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase/metabolismo , Norbornanos , Fosfatidilcolinas/metabolismo , Inibidores de Fosfodiesterase/farmacologia , RNA Mensageiro , Proteínas de Ligação a RNA/metabolismo , Ribonucleases , Tiocarbamatos , Tionas/farmacologia , Fosfolipases Tipo C/antagonistas & inibidoresRESUMO
Peroxynitrite (ONOO(-)), a toxic product of the free radicals nitric oxide and superoxide, has been implicated in the pathogenesis of CNS inflammatory diseases, including multiple sclerosis and its animal correlate experimental autoimmune encephalomyelitis (EAE). In this study we have assessed the mode of action of uric acid (UA), a purine metabolite and ONOO(-) scavenger, in the treatment of EAE. We show that if administered to mice before the onset of clinical EAE, UA interferes with the invasion of inflammatory cells into the CNS and prevents development of the disease. In mice with active EAE, exogenously administered UA penetrates the already compromised blood-CNS barrier, blocks ONOO(-)-mediated tyrosine nitration and apoptotic cell death in areas of inflammation in spinal cord tissues and promotes recovery of the animals. Moreover, UA treatment suppresses the enhanced blood-CNS barrier permeability characteristic of EAE. We postulate that UA acts at two levels in EAE: 1) by protecting the integrity of the blood-CNS barrier from ONOO(-)-induced permeability changes such that cell invasion and the resulting pathology is minimized; and 2) through a compromised blood-CNS barrier, by scavenging the ONOO(-) directly responsible for CNS tissue damage and death.
Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Sequestradores de Radicais Livres/farmacologia , Esclerose Múltipla/tratamento farmacológico , Nitratos/metabolismo , Ácido Úrico/farmacologia , Animais , Apoptose/efeitos dos fármacos , Modelos Animais de Doenças , Encefalomielite Autoimune Experimental/tratamento farmacológico , Feminino , Camundongos , Esclerose Múltipla/patologia , Esclerose Múltipla/fisiopatologia , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo , Medula Espinal/patologia , Tirosina/análogos & derivados , Tirosina/metabolismoRESUMO
We have recently demonstrated that increased blood-CNS barrier permeability and CNS inflammation in a conventional mouse model of experimental allergic encephalomyelitis are dependent upon the production of peroxynitrite (ONOO(-)), a product of the free radicals NO* and superoxide (O2*(-)). To determine whether this is a reflection of the physiological contribution of ONOO(-) to an immune response against a neurotropic pathogen, we have assessed the effects on adult rats acutely infected with Borna disease virus (BDV) of administration of uric acid (UA), an inhibitor of select chemical reactions associated with ONOO(-). The pathogenesis of acute Borna disease in immunocompetent adult rats results from the immune response to the neurotropic BDV, rather than the direct effects of BDV infection of neurons. An important stage in the BDV-specific neuroimmune response is the invasion of inflammatory cells into the CNS. UA treatment inhibited the onset of clinical disease, and prevented the elevated blood-brain barrier permeability as well as CNS inflammation seen in control-treated BDV-infected rats. The replication and spread of BDV in the CNS were unchanged by the administration of UA, and only minimal effects on the immune response to BDV Ags were observed. These results indicate that the CNS inflammatory response to neurotropic virus infection is likely to be dependent upon the activity of ONOO(-) or its products on the blood-brain barrier.
Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Doença de Borna/imunologia , Vírus da Doença de Borna/imunologia , Encéfalo/imunologia , Quimiotaxia de Leucócito/fisiologia , Encefalite Viral/imunologia , Sequestradores de Radicais Livres/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Ácido Peroxinitroso/fisiologia , Tirosina/análogos & derivados , Ácido Úrico/uso terapêutico , Doença Aguda , Animais , Antígenos Virais/imunologia , Doença de Borna/patologia , Doença de Borna/virologia , Vírus da Doença de Borna/fisiologia , Encéfalo/metabolismo , Encéfalo/patologia , Encéfalo/virologia , Química Encefálica/efeitos dos fármacos , Quimiotaxia de Leucócito/efeitos dos fármacos , Encefalite Viral/patologia , Encefalite Viral/virologia , Feminino , Sequestradores de Radicais Livres/farmacologia , Radicais Livres , Perfilação da Expressão Gênica , Imunocompetência , Inflamação , Contagem de Linfócitos , Proteínas do Tecido Nervoso/análise , Neurônios/enzimologia , Fármacos Neuroprotetores/farmacologia , Óxido Nítrico Sintase/análise , Óxido Nítrico Sintase Tipo II , Oxirredução , Reação em Cadeia da Polimerase , Ratos , Ratos Endogâmicos Lew , Subpopulações de Linfócitos T/efeitos dos fármacos , Tirosina/análise , Ácido Úrico/farmacologia , Replicação Viral/efeitos dos fármacosRESUMO
Nitric oxide (NO) has been implicated as a pathogenic mediator in a variety of central nervous system (CNS) disease states, including the animal model of multiple sclerosis (MS) and experimental allergic encephalomyelitis. We have examined post-mortem brain tissues collected from patients previously diagnosed with MS, as well as tissues collected from the brains of patients dying without neuropathies. Both Northern blot analysis and reverse transcriptase (RT)-driven in situ PCR (RT-in situ PCR) studies demonstrated that inducible NO synthase (iNOS) mRNA was present in the brain tissues from MS patients but was absent in equivalent tissues from normal controls. We have also performed experiments identifying the cell type responsible for iNOS expression by RT-in situ PCR in combination with immunohistochemistry. Concomitantly, we analyzed the tissues for the presence of the NO reaction product nitrotyrosine to demonstrate the presence of a protein nitrosylation adduct. We report here that iNOS mRNA was detectable in the brains of 100% of the CNS tissues from seven MS patients examined but in none of the three normal brains. RT-in situ PCR experiments also demonstrated the presence of iNOS mRNA in the cytoplasm of cells that also expressed the ligand recognized by the Ricinus communis agglutinin 1 (RCA-1), a monocyte/macrophage lineage marker. Additionally, specific labeling of cells was observed when brain tissues from MS patients were exposed to antisera reactive with nitrotyrosine residues but was significantly less plentiful in brain tissue from patients without CNS disease. These results demonstrate that iNOS, one of the enzymes responsible for the production of NO, is expressed at significant levels in the brains of patients with MS and may contribute to the pathology associated with the disease.
Assuntos
Encéfalo/enzimologia , Isoenzimas/metabolismo , Esclerose Múltipla/enzimologia , Óxido Nítrico Sintase/metabolismo , Lectinas de Plantas , Autopsia , Sequência de Bases , Northern Blotting , Encéfalo/patologia , Células Cultivadas , Primers do DNA , Ativação Enzimática , Indução Enzimática , Epitélio , Humanos , Imuno-Histoquímica , Lectinas , Pulmão , Macrófagos/enzimologia , Macrófagos/patologia , Dados de Sequência Molecular , Esclerose Múltipla/patologia , Óxido Nítrico Sintase/biossíntese , Reação em Cadeia da Polimerase/métodos , RNA Mensageiro/análise , RNA Mensageiro/biossíntese , RNA Mensageiro/metabolismo , Valores de ReferênciaRESUMO
A new approach to the production and delivery of vaccine antigens is the use of engineered amino virus-based vectors. A chimeric peptide containing antigenic determinants from rabies virus glycoprotein (G protein) (amino acids 253-275) and nucleoprotein (N protein) (amino acids 404-418) was PCR-amplified and cloned as a translational fusion product with the alfalfa mosaic virus (AlMV) coat protein (CP). This recombinant CP was expressed in two plant virus-based expression systems. The first one utilized transgenic Nicotiana tabacum cv. Samsun NN plants providing replicative functions in trans for full-length infectious RNA3 of AlMV (NF1-g24). The second one utilized Nicotiana benthamiana and spinach (Spinacia oleracea) plants using autonomously replicating tobacco mosaic virus (TMV) lacking native CP (Av/A4-g24). Recombinant virus containing the chimeric rabies virus epitope was isolated from infected transgenic N. tabacum cv. Samsun NN plants and used for parenteral immunization of mice. Mice immunized with recombinant virus were protected against challenge infection. Based on the previously demonstrated efficacy of this plant virus-based experimental rabies vaccine when orally administered to mice in virus-infected unprocessed raw spinach leaves, we assessed its efficacy in human volunteers. Three of five volunteers who had previously been immunized against rabies virus with a conventional vaccine specifically responded against the peptide antigen after ingesting spinach leaves infected with the recombinant virus. When rabies virus non-immune individuals were fed the same material, 5/9 demonstrated significant antibody responses to either rabies virus or AlMV. Following a single dose of conventional rabies virus vaccine, three of these individuals showed detectable levels of rabies virus-neutralizing antibodies, whereas none of five controls revealed these antibodies. These findings provide clear indication of the potential of the plant virus-based expression systems as supplementary oral booster for rabies vaccinations.